{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T22:56:55Z","timestamp":1793055415107,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T00:00:00Z","timestamp":1720051200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T00:00:00Z","timestamp":1720051200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/100004339","name":"Sanofi","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004339","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Neurol"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1007\/s00415-024-12543-6","type":"journal-article","created":{"date-parts":[[2024,7,4]],"date-time":"2024-07-04T15:02:33Z","timestamp":1720105353000},"page":"5846-5852","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Real-world data of in-hospital administration of alglucosidase alfa in French patients with Pompe disease: results from the National Claims Database"],"prefix":"10.1007","volume":"271","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7211-4694","authenticated-orcid":false,"given":"Shahram","family":"Attarian","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emmanuelle Salort","family":"Campana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stanislas","family":"Perrier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Afonso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre","family":"Karam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nassima","family":"Hai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pascal","family":"Laforet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,7,4]]},"reference":[{"issue":"9646","key":"12543_CR1","doi-asserted-by":"publisher","first-page":"1342","DOI":"10.1016\/S0140-6736(08)61555-X","volume":"372","author":"AT van der Ploeg","year":"2008","unstructured":"van der Ploeg AT, Reuser AJ (2008) Pompe\u2019s disease. Lancet 372(9646):1342\u20131353","journal-title":"Lancet"},{"issue":"5","key":"12543_CR2","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1097\/01.gim.0000218152.87434.f3","volume":"8","author":"PS Kishnani","year":"2006","unstructured":"Kishnani PS, Steiner RD, Bali D, Berger K, Byrne BJ, Case LE et al (2006) Pompe disease diagnosis and management guideline. Genet Med 8(5):267\u2013288","journal-title":"Genet Med"},{"issue":"6","key":"12543_CR3","doi-asserted-by":"publisher","first-page":"1219","DOI":"10.1002\/jimd.12272","volume":"43","author":"C Semplicini","year":"2020","unstructured":"Semplicini C, De Antonio M, Taouagh N, B\u00e9hin A, Bouhour F, Echaniz-Laguna A et al (2020) Long-term benefit of enzyme replacement therapy with alglucosidase alfa in adults with Pompe disease: prospective analysis from the French Pompe Registry. J Inherit Metab Dis 43(6):1219\u20131231","journal-title":"J Inherit Metab Dis"},{"issue":"6","key":"12543_CR4","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1007\/s10545-018-0243-7","volume":"41","author":"C Semplicini","year":"2018","unstructured":"Semplicini C, Letard P, De Antonio M, Taouagh N, Perniconi B, Bouhour F et al (2018) Late-onset Pompe disease in France: molecular features and epidemiology from a nationwide study. J Inherit Metab Dis 41(6):937\u2013946","journal-title":"J Inherit Metab Dis"},{"issue":"1","key":"12543_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/bmjpo-2017-000182","volume":"2","author":"N Elenga","year":"2018","unstructured":"Elenga N, Verloes A, Mrsic Y, Basurko C, Schaub R, Cuadro-Alvarez E et al (2018) Incidence of infantile Pompe disease in the Maroon population of French Guiana. BMJ Paediatr Open 2(1):e000182","journal-title":"BMJ Paediatr Open"},{"key":"12543_CR6","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2019\/125141s222lbl.pdf, Accessed 24 July 2022"},{"key":"12543_CR7","unstructured":"https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2010\/125291lbl.pdf, Accessed on 24 July 2022"},{"key":"12543_CR8","unstructured":"Myozyme, INN-alglucosidase alfa (europa.eu); Accessed 10 October 2023"},{"issue":"3","key":"12543_CR9","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1203\/PDR.0b013e3181b24e94","volume":"66","author":"PS Kishnani","year":"2009","unstructured":"Kishnani PS, Corzo D, Leslie ND, Gruskin D, Van der Ploeg A, Clancy JP et al (2009) Early treatment with alglucosidase alpha prolongs long-term survival of infants with Pompe disease. Pediatr Res 66(3):329\u2013335","journal-title":"Pediatr Res"},{"issue":"2","key":"12543_CR10","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1212\/01.wnl.0000251268.41188.04","volume":"68","author":"PS Kishnani","year":"2007","unstructured":"Kishnani PS, Corzo D, Nicolino M, Byrne B, Mandel H, Hwu WL et al (2007) Recombinant human acid [alpha]-glucosidase: major clinical benefits in infantile-onset Pompe disease. Neurology 68(2):99\u2013109","journal-title":"Neurology"},{"issue":"3","key":"12543_CR11","doi-asserted-by":"publisher","first-page":"210","DOI":"10.1097\/GIM.0b013e31819d0996","volume":"11","author":"M Nicolino","year":"2009","unstructured":"Nicolino M, Byrne B, Wraith JE, Leslie N, Mandel H, Freyer DR et al (2009) Clinical outcomes after long-term treatment with alglucosidase alfa in infants and children with advanced Pompe disease. Genet Med 11(3):210\u2013219","journal-title":"Genet Med"},{"issue":"15","key":"12543_CR12","doi-asserted-by":"publisher","first-page":"1396","DOI":"10.1056\/NEJMoa0909859","volume":"362","author":"AT van der Ploeg","year":"2010","unstructured":"van der Ploeg AT, Clemens PR, Corzo D, Escolar DM, Florence J, Groeneveld GJ et al (2010) A randomized study of alglucosidase alfa in late-onset Pompe\u2019s disease. N Engl J Med 362(15):1396\u20131406","journal-title":"N Engl J Med"},{"issue":"10","key":"12543_CR13","doi-asserted-by":"publisher","first-page":"1284","DOI":"10.1038\/gim.2018.2","volume":"20","author":"SH Hahn","year":"2018","unstructured":"Hahn SH, Kronn D, Leslie ND, Pena LDM, Tanpaiboon P, Gambello MJ et al (2018) Efficacy, safety profile, and immunogenicity of alglucosidase alfa produced at the 4000-liter scale in US children and adolescents with Pompe disease: ADVANCE, a phase IV, open-label, prospective study. Genet Med 20(10):1284\u20131294","journal-title":"Genet Med"},{"key":"12543_CR14","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.ijcard.2018.07.091","volume":"269","author":"CI van Capelle","year":"2018","unstructured":"van Capelle CI, Poelman E, Frohn-Mulder IM, Koopman LP, van den Hout JMP, R\u00e9gal L et al (2018) Cardiac outcome in classic infantile Pompe disease after 13 years of treatment with recombinant human acid alpha-glucosidase. Int J Cardiol 269:104\u2013110","journal-title":"Int J Cardiol"},{"issue":"7","key":"12543_CR15","doi-asserted-by":"publisher","first-page":"2482","DOI":"10.1007\/s00415-021-10409-9","volume":"268","author":"K Gutschmidt","year":"2021","unstructured":"Gutschmidt K, Musumeci O, D\u00edaz-Manera J, Chien YH, Knop KC, Wenninger S et al (2021) STIG study: real-world data of long-term outcomes of adults with Pompe disease under enzyme replacement therapy with alglucosidase alfa. J Neurol 268(7):2482\u20132492","journal-title":"J Neurol"},{"issue":"2","key":"12543_CR16","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1007\/s40120-019-00157-4","volume":"8","author":"H Nagura","year":"2019","unstructured":"Nagura H, Hokugo J, Ueda K (2019) Long-term observation of the safety and effectiveness of enzyme replacement therapy in Japanese patients with pompe disease: results from the post-marketing surveillance. Neurol Ther 8(2):397\u2013409","journal-title":"Neurol Ther"},{"issue":"5","key":"12543_CR17","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1007\/s40259-023-00609-2","volume":"37","author":"IAM Ditters","year":"2023","unstructured":"Ditters IAM, van Kooten HA, van der Beek N, Hardon JF, Ismailova G, Brusse E et al (2023) Home-based infusion of alglucosidase alfa can safely be implemented in adults with late-onset pompe disease: lessons learned from 18,380 infusions. BioDrugs 37(5):685\u2013698","journal-title":"BioDrugs"},{"issue":"4","key":"12543_CR18","doi-asserted-by":"publisher","first-page":"1181","DOI":"10.1111\/ene.15222","volume":"29","author":"C Tard","year":"2022","unstructured":"Tard C, Salort-Campana E, Michaud M, Spinazzi M, Nadaj Pakleza A, Durr H et al (2022) Motor and respiratory decline in patients with late onset Pompe disease after cessation of enzyme replacement therapy during COVID-19 pandemic. Eur J Neurol 29(4):1181\u20131186","journal-title":"Eur J Neurol"},{"issue":"6","key":"12543_CR19","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1016\/j.neurol.2020.04.004","volume":"176","author":"G Sol\u00e9","year":"2020","unstructured":"Sol\u00e9 G, Salort-Campana E, Pereon Y, Stojkovic T, Wahbi K, Cintas P et al (2020) Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network. Rev Neurol (Paris) 176(6):507\u2013515","journal-title":"Rev Neurol (Paris)"},{"issue":"12","key":"12543_CR20","doi-asserted-by":"publisher","first-page":"2783","DOI":"10.1007\/s00415-018-9065-7","volume":"265","author":"O Scheidegger","year":"2018","unstructured":"Scheidegger O, Leupold D, Sauter R, Findling O, R\u00f6sler KM, Hundsberger T (2018) 36-Months follow-up assessment after cessation and resuming of enzyme replacement therapy in late onset Pompe disease: data from the Swiss Pompe Registry. J Neurol 265(12):2783\u20132788","journal-title":"J Neurol"},{"issue":"2","key":"12543_CR21","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1590\/0004-282X20150194","volume":"74","author":"JC Llerena Junior","year":"2016","unstructured":"Llerena Junior JC, Nascimento OJ, Oliveira AS, Dourado Junior ME, Marrone CD, Siqueira HH et al (2016) Guidelines for the diagnosis, treatment and clinical monitoring of patients with juvenile and adult Pompe disease. Arq Neuropsiquiatr 74(2):166\u2013176","journal-title":"Arq Neuropsiquiatr"},{"issue":"12","key":"12543_CR22","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1515\/jpem-2018-0336","volume":"31","author":"M Spada","year":"2018","unstructured":"Spada M, Pagliardini V, Ricci F, Biamino E, Mongini T, Porta F (2018) Early higher dosage of alglucosidase alpha in classic Pompe disease. J Pediatr Endocrinol Metab 31(12):1343\u20131347","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"1","key":"12543_CR23","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1186\/s13023-022-02232-w","volume":"17","author":"D Genevaz","year":"2022","unstructured":"Genevaz D, Arnoux A, Marcel C, Brassier A, Pichard S, Feillet F et al (2022) Transition from child to adult health care for patients with lysosomal storage diseases in France: current status and priorities-the TENALYS study, a patient perspective survey. Orphanet J Rare Dis 17(1):68","journal-title":"Orphanet J Rare Dis"},{"key":"12543_CR24","unstructured":"Nexviadyme, INN-avalglucosidase alfa (europa.eu); Accessed on April 22, 2024"}],"container-title":["Journal of Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12543-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00415-024-12543-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00415-024-12543-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,5]],"date-time":"2024-09-05T12:18:11Z","timestamp":1725538691000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00415-024-12543-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,7,4]]},"references-count":24,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2024,9]]}},"alternative-id":["12543"],"URL":"https:\/\/doi.org\/10.1007\/s00415-024-12543-6","relation":{},"ISSN":["0340-5354","1432-1459"],"issn-type":[{"value":"0340-5354","type":"print"},{"value":"1432-1459","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,7,4]]},"assertion":[{"value":"2 April 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 June 2024","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 June 2024","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 July 2024","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Stanislas Perrier, Marion Afonso, and Nassima Hai are Sanofi employees and may hold stock and\/or stock options.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}}]}}